JP7065085B2 - Cd6のリン酸化を低減させるためのイトリズマブの使用 - Google Patents

Cd6のリン酸化を低減させるためのイトリズマブの使用 Download PDF

Info

Publication number
JP7065085B2
JP7065085B2 JP2019520731A JP2019520731A JP7065085B2 JP 7065085 B2 JP7065085 B2 JP 7065085B2 JP 2019520731 A JP2019520731 A JP 2019520731A JP 2019520731 A JP2019520731 A JP 2019520731A JP 7065085 B2 JP7065085 B2 JP 7065085B2
Authority
JP
Japan
Prior art keywords
alcam
antibody
itrizumab
phosphorylation
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019520731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504597A5 (cg-RX-API-DMAC10.html
JP2020504597A (ja
Inventor
ナーイル,プラディプ
サーハー,アリンダム
サダシヴァラオ,ラヴィンドラ,ベラビナコディジ
ブガーニ,ウシャ
メラーコーデ,ラマクリシュナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of JP2020504597A publication Critical patent/JP2020504597A/ja
Publication of JP2020504597A5 publication Critical patent/JP2020504597A5/ja
Application granted granted Critical
Publication of JP7065085B2 publication Critical patent/JP7065085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrically Operated Instructional Devices (AREA)
JP2019520731A 2016-10-18 2017-10-16 Cd6のリン酸化を低減させるためのイトリズマブの使用 Expired - Fee Related JP7065085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641035602 2016-10-18
IN201641035602 2016-10-18
PCT/IB2017/056403 WO2018073721A1 (en) 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of cd6

Publications (3)

Publication Number Publication Date
JP2020504597A JP2020504597A (ja) 2020-02-13
JP2020504597A5 JP2020504597A5 (cg-RX-API-DMAC10.html) 2020-11-26
JP7065085B2 true JP7065085B2 (ja) 2022-05-11

Family

ID=62019244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520731A Expired - Fee Related JP7065085B2 (ja) 2016-10-18 2017-10-16 Cd6のリン酸化を低減させるためのイトリズマブの使用

Country Status (8)

Country Link
US (2) US20190248913A1 (cg-RX-API-DMAC10.html)
EP (1) EP3528846A4 (cg-RX-API-DMAC10.html)
JP (1) JP7065085B2 (cg-RX-API-DMAC10.html)
KR (1) KR102469798B1 (cg-RX-API-DMAC10.html)
AU (1) AU2017345390B2 (cg-RX-API-DMAC10.html)
CA (1) CA3076861A1 (cg-RX-API-DMAC10.html)
IL (1) IL266087B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018073721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
US20230076643A1 (en) * 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) * 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Clinical and Experimental Immunology,Vol.162,2010年,p.116-130
mAbs,2014年,Vol.6, No.3,p.782-792
Molecular and Cellular Biology,2006年,Vol.26, No.17,p.6727-6738
Nat Immunol,2014年,15(4),P.1-32, Supplementary Information

Also Published As

Publication number Publication date
KR102469798B1 (ko) 2022-11-22
KR20190070957A (ko) 2019-06-21
EP3528846A1 (en) 2019-08-28
EP3528846A4 (en) 2020-06-03
US20190248913A1 (en) 2019-08-15
WO2018073721A1 (en) 2018-04-26
AU2017345390A1 (en) 2019-05-02
IL266087B1 (en) 2023-10-01
IL266087B2 (en) 2024-02-01
US20240101700A1 (en) 2024-03-28
JP2020504597A (ja) 2020-02-13
AU2017345390B2 (en) 2024-08-08
IL266087A (en) 2019-06-30
CA3076861A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US20220193199A1 (en) Il-15 and il-15ralpha sushi domain based modulokines
JP7565678B2 (ja) 組合せ医薬組成物
US20240101700A1 (en) Use of itolizumab to reduce phosphorylation of cd6
WO2008138017A2 (en) Methods and compositions for modifying t cell immune responses and inflammation
JP2020520985A (ja) がん療法における免疫関連有害事象の治療のための可溶性cd24の使用方法
KR20020086540A (ko) Il-18 저해물질의 용도
Bloemendaal et al. Anti–tumor necrosis factor with a glyco-engineered Fc-region has increased efficacy in mice with colitis
Lim et al. TNF-α: a paradigm of paradox and complexity in multiple sclerosis and its animal models
JP2020503251A (ja) モノクローナル抗体および狼瘡の処置のための使用の方法
US20220307035A1 (en) Composition for preventing or treating cancer
HK40074884B (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40102087A (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40074884A (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40004449A (en) Il-15 and il-15raplha sushi domain based modulokines
HK40004449B (en) Il-15 and il-15ralpha sushi domain based modulokines
Kaul et al. New therapies for systemic lupus erythematosus: has the future arrived?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220425

R150 Certificate of patent or registration of utility model

Ref document number: 7065085

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees